T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

What is the purpose of this trial?

The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.


Participation Guidelines

Ages: 18 - 45 years

Gender: Both


University of California, San Francisco

Dates: 05/25/2017 - 07/31/2021

Last Updated: 05/26/2017

Study HIC#: 1607018090

Get Involved

For more information about this study, contact:
Linda Marie Rink
+1 203-737-4510
linda.rink@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigator

Kevan Herold

Principal Investigator